



**PRESS RELEASE**

## **Amoéba's Board of Directors nominates Mr Bernard Ambolet as new independent director**

**Chassieu, September 21<sup>st</sup>, 2018 – AMOEBA** (FR0011051598 - AMEBA) producer of a biological biocide capable of eliminating bacterial risks in water, plant protection and wound care announced today the provisional nomination of Mr Bernard AMBOLET as an independent member of the board of Directors. Mr AMBOLET replaces EUREKAP! company for the remainder of its term, i.e., until the Ordinary Annual General Meeting called to review the accounts for the period ending December 31<sup>st</sup>, 2022. This nomination will be subject to approval during the next Annual General Meeting.

The qualification of independence has been retained by the Board of Directors in compliance with the independence criteria defined by the MiddleNext Code.

### **Bernard AMBOLET**

Agriculture engineer, Bernard AMBOLET spent 9 years in a technical research institute (Arvalis – Plant institute) and 27 years within the BAYER France group as:

- Head of Scientific Affairs
- Branch manager
- In charge of experimentations and registration of Phyto-pharmaceutical products for the French market

In addition to his culture integrated protection skills, he has a wide experience in management, strategic and systemic approach.

Bernard AMBOLET is a regular member of the French Academy of Agriculture and member of the board of the AFPP (French association for Plant Protection)

Moreover, Amoéba announces the resignation- effective on May 25th, 2018- of Mrs Marie Christine GROS FAVROT from the Board of Directors.

Within the company's governance evolution, the company is looking for new profiles to meet Amoéba new challenges.

*"I am pleased to welcome Bernard AMBOLET in the Board of Directors. Bernard will provide the company with his expertise on both regulatory and strategic issues on our new challenge in plant protection. I thank Eureka! company and more particularly its representative Guy RIGAUD who has supported the company since 2011"* declares **Fabrice PLASSON, Chairman of AMOEBA.**



## About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn <sup>(1)</sup> on a global chemical biocide market for water treatment, evaluated at €21Bn <sup>(2)</sup> and on the biocontrol market for plant protection estimated globally at €1.6Bn <sup>(4)</sup>. In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million <sup>(3)</sup> in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPI France Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on [www.amoeba-biocide.com](http://www.amoeba-biocide.com).

*(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013*

*(2): Sources combined by Amoéba from water treaters, Freedomia, Eurostat et MarketsandMarkets*

*(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017*

*(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK*

## Contacts :

### **Amoéba**

Valérie FILIATRE

Directeur administratif et Financier

04 26 69 16 00

[valerie.filiatre@amoeba-biocide.com](mailto:valerie.filiatre@amoeba-biocide.com)

### **Actifin**

Ghislaine GASPARETTO

Communication financière

01 56 88 11 11

[ggasparetto@actifin.fr](mailto:ggasparetto@actifin.fr)

## **Disclaimer**

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (*Autorité des Marchés Financiers*) on April 27, 2018 (a copy of which is available on [www.amoeba-biocide.com](http://www.amoeba-biocide.com)). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.